In Huntington's, hope meets the hurdle of clinical trials
When an experimental therapy for a currently untreatable disease reaches clinical trials, there's excitement and hope. But there's also desperation among patients who don't meet the criteria to enroll.
Such is the case with a clinical trial now underway to test a Roche treatment for Huntington's disease. The drug, called RG6042, is aimed at the genetic roots of the disease, and if it's successful, it could be life-changing for those affected by the genetic disorder. As with all trials, though, Roche's can only include so many people. So some Huntington's patients — those who are too old, too young, have other health conditions, or just couldn't get a spot — have been turned away from participating.
STAT's Andrew Joseph has the story of a trial that for now looks like the best, and really the only, option available to these patients, with multimedia from Matthew Orr and Dom Smith.
Read more.
Such is the case with a clinical trial now underway to test a Roche treatment for Huntington's disease. The drug, called RG6042, is aimed at the genetic roots of the disease, and if it's successful, it could be life-changing for those affected by the genetic disorder. As with all trials, though, Roche's can only include so many people. So some Huntington's patients — those who are too old, too young, have other health conditions, or just couldn't get a spot — have been turned away from participating.
STAT's Andrew Joseph has the story of a trial that for now looks like the best, and really the only, option available to these patients, with multimedia from Matthew Orr and Dom Smith.
Read more.
No hay comentarios:
Publicar un comentario